| Ana Milosevic Michunovich, DO | |
|
4800 E Johnson Ave, Jonesboro, AR 72401-8413 | |
| (708) 936-1000 | |
| Not Available |
| Full Name | Ana Milosevic Michunovich |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 9 Years |
| Location | 4800 E Johnson Ave, Jonesboro, Arkansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033596663 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | E-12183 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Memorial Hospital Jonesboro, Inc. | Jonesboro, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeast Arkansas Clinic Charitable Foundation, Inc. | 2961547526 | 228 |
News Archive
A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.
Today's health policy headlines highlight HHS Secretary Sebelius' defense of the Obama administration's Medicare nominee as well as the AMA's push to fix scheduled reductions in Medicare physician payments.
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
Vanda Pharmaceuticals Inc. presented additional entrainment and patient-level clinical data at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies in Baltimore, from its SET (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Disorder) Phase III studies of tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in totally blind individuals.
Certificate of Need, a form of state government regulation designed to keep mortality rates and health care costs down, appears to do neither for heart bypass surgery, according to a health economics researcher at Rice University and Baylor College of Medicine (BCM).
› Verified 5 days ago
| Entity Name | Northeast Arkansas Clinic Charitable Foundation, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861721839 PECOS PAC ID: 2961547526 Enrollment ID: O20100315000190 |
News Archive
A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.
Today's health policy headlines highlight HHS Secretary Sebelius' defense of the Obama administration's Medicare nominee as well as the AMA's push to fix scheduled reductions in Medicare physician payments.
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
Vanda Pharmaceuticals Inc. presented additional entrainment and patient-level clinical data at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies in Baltimore, from its SET (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Disorder) Phase III studies of tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in totally blind individuals.
Certificate of Need, a form of state government regulation designed to keep mortality rates and health care costs down, appears to do neither for heart bypass surgery, according to a health economics researcher at Rice University and Baylor College of Medicine (BCM).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ana Milosevic Michunovich, DO 361 Southwest Dr # 107, Jonesboro, AR 72401-5854 Ph: (602) 334-0602 | Ana Milosevic Michunovich, DO 4800 E Johnson Ave, Jonesboro, AR 72401-8413 Ph: (708) 936-1000 |
News Archive
A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.
Today's health policy headlines highlight HHS Secretary Sebelius' defense of the Obama administration's Medicare nominee as well as the AMA's push to fix scheduled reductions in Medicare physician payments.
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
Vanda Pharmaceuticals Inc. presented additional entrainment and patient-level clinical data at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies in Baltimore, from its SET (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Disorder) Phase III studies of tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in totally blind individuals.
Certificate of Need, a form of state government regulation designed to keep mortality rates and health care costs down, appears to do neither for heart bypass surgery, according to a health economics researcher at Rice University and Baylor College of Medicine (BCM).
› Verified 5 days ago
Mrs. Jordan Ramm, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1705 Latourette Ln, Jonesboro, AR 72404 Phone: 870-935-7550 | |
Ms. Mallory Breanne Long, DPT Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 1107 E Matthews Ave Ste 100, Jonesboro, AR 72401 Phone: 870-933-6393 Fax: 870-933-6763 | |
Mira Zelin, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 4800 E Johnson Ave, Jonesboro, AR 72401 Phone: 870-936-5040 Fax: 870-936-5039 | |
Dr. Zhangliang Ma, MD & PHD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 4802 E Johnson Ave, Jonesboro, AR 72401 Phone: 870-936-8000 Fax: 870-934-3625 | |
Dr. Virendar Kumar Verma, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 1201 Fleming Ave, Health South Rehablitation Hospital Of Jonesboro, Jonesboro, AR 72403 Phone: 870-275-6010 Fax: 870-203-0945 | |
Jonathan P Vecchiarelli, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 4916 Medical Blvd, Jonesboro, AR 72405 Phone: 870-936-8000 Fax: 870-934-3625 |